{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:56:15Z","timestamp":1775030175318,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.kint.2021.10.024","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T20:23:37Z","timestamp":1636575817000},"page":"663-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["How the amyloid fibril has unraveled: lessons for nephrology"],"prefix":"10.1016","volume":"101","author":[{"given":"Nelson","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.10.024_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.kint.2021.10.024_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","article-title":"Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition","volume":"49","author":"Muchtar","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.kint.2021.10.024_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.024_bib4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.024_bib5","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.10.024_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.024_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2021.10.024_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.024_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.10.024_bib10","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing: the new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2021.10.024_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214094","article-title":"Associations between access to healthcare, environmental quality, and end-stage renal disease survival time: proportional-hazards models of over 1,000,000 people over 14 years","volume":"14","author":"Kosnik","year":"2019","journal-title":"PLoS One"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821010516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821010516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:28:40Z","timestamp":1775021320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821010516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0085253821010516"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.10.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How the amyloid fibril has unraveled: lessons for nephrology","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}